news
11 February 2020
Da Volterra Announces Positive Top-line Results from a Phase 2 Clinical Trial Evaluating DAV132 in 260 Patients
• First clinical study evaluating DAV132 in patients • Primary endpoint met: DAV132 was safe for use in…
This year’s event in Vienna will bring together the “who’s who” from the biotech, pharma and finance segments to allow delegates to meet more key decision makers in three days of partnering meetings than they could in a whole year.
We look forward to sharing updates on DAV132 and meeting with both current and potential partners!
Do not hesitate to reach out to our Business Development team at bd@davolterra.com
Website Event link here
